Qingdao Haier Biomedical Co Ltd (688139) - Total Assets
Based on the latest financial reports, Qingdao Haier Biomedical Co Ltd (688139) holds total assets worth CN¥5.83 Billion CNY (≈ $852.63 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Qingdao Haier Biomedical Co Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Qingdao Haier Biomedical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 688139 stock market capitalisation for the company's overall valuation and market capitalisation.
Qingdao Haier Biomedical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Qingdao Haier Biomedical Co Ltd's total assets of CN¥5.83 Billion consist of 45.9% current assets and 54.1% non-current assets. Review 688139 liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.6% |
| Accounts Receivable | CN¥404.42 Million | 7.0% |
| Inventory | CN¥345.47 Million | 6.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥360.50 Million | 6.2% |
| Goodwill | CN¥758.24 Million | 13.1% |
Asset Composition Trend (2016–2025)
This chart illustrates how Qingdao Haier Biomedical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Qingdao Haier Biomedical Co Ltd stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Qingdao Haier Biomedical Co Ltd's current assets represent 45.9% of total assets in 2025, a decrease from 90.1% in 2016.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2025, up from 14.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 1.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 13.1% of total assets.
Qingdao Haier Biomedical Co Ltd Competitors by Total Assets
Key competitors of Qingdao Haier Biomedical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Medartis Holding AG
SW:MED
|
Switzerland | CHF610.05 Million |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236
|
China | CN¥3.54 Billion |
|
PULSION Medical Systems SE
MU:PUS
|
Germany | €35.15 Million |
Qingdao Haier Biomedical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.66 | 2.91 | 2.90 |
| Quick Ratio | 2.34 | 2.57 | 2.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.75 Billion | CN¥1.71 Billion | CN¥2.22 Billion |
Qingdao Haier Biomedical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Qingdao Haier Biomedical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.22 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 0.1% |
| Total Assets | CN¥5.79 Billion |
| Market Capitalization | $1.45 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Qingdao Haier Biomedical Co Ltd's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Qingdao Haier Biomedical Co Ltd's assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Qingdao Haier Biomedical Co Ltd (2016–2025)
The table below shows the annual total assets of Qingdao Haier Biomedical Co Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.79 Billion ≈ $847.48 Million |
+0.07% |
| 2024-12-31 | CN¥5.79 Billion ≈ $846.89 Million |
+4.74% |
| 2023-12-31 | CN¥5.53 Billion ≈ $808.58 Million |
+0.67% |
| 2022-12-31 | CN¥5.49 Billion ≈ $803.21 Million |
+12.02% |
| 2021-12-31 | CN¥4.90 Billion ≈ $717.00 Million |
+24.28% |
| 2020-12-31 | CN¥3.94 Billion ≈ $576.93 Million |
+29.69% |
| 2019-12-31 | CN¥3.04 Billion ≈ $444.85 Million |
+36.46% |
| 2018-12-31 | CN¥2.23 Billion ≈ $325.99 Million |
+87.10% |
| 2017-12-31 | CN¥1.19 Billion ≈ $174.23 Million |
+25.43% |
| 2016-12-31 | CN¥949.27 Million ≈ $138.91 Million |
-- |
About Qingdao Haier Biomedical Co Ltd
Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, and RTMD products; and CO2 incubation, standard … Read more